SCIGEN SECURES ADDITIONAL TERRITORIES FOR HUMAN INSULIN

ASX Announcement and Media Release

Monday 16 January 2012

SciGen Ltd

SCIGEN SECURES RECOMBINANT HUMAN INSULIN MARKETING LICENCE FOR ADDITIONAL TERRITORIES

SciGen Limited (ASX:SIE) announced today that the Company has renegotiated the terms of its licensing agreement with Ferring S.A. and Bio-Technology General (Israel) Ltd. for the manufacture and sale of recombinant human insulin resulting in an expansion of rights.
The key changes to the licence agreements are:
SciGen will have access to 40 countries divided in the following groups:
(i) 21 countries on an exclusive basis and
(ii) 19 countries on a semi-exclusive basis
The scope of the transaction is as follows:
(i) SciGen will maintain exclusive rights to 9 countries
(ii) SciGen will obtain additional 12 countries on an exclusive basis
(iii) SciGen will obtain additional 8 countries on a semi-exclusive basis
(iv) SciGen will obtain 50% of royalties receivable by Ferring from 11 countries for which SciGen will convert its exclusive license into a semi-exclusive license
This is a significant commercial transaction as it will enable SciGen to enter into the growing recombinant human insulin markets in the Middle East and Africa.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.
SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical
products under exclusive licensing arrangements. SciGen's portfolio currently includes

SciGen Limited ARBN 101 318 852 Suite 1, 13B Narabang Way, Belrose, NSW 2085 Australia

Telephone : + 61 2 9485 1800 Facsimile : + 61 2 9485 1888 Website: www.scigenltd.com
proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.
SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.
SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.
SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, Vietnam, China, India, Israel and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China and a
contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd [phone] Email: [e-mail]	Slawomir Ziegert CEO SciGen Ltd [phone]

SciGen Limited ARBN 101 318 852 Suite 1, 13B Narabang Way, Belrose, NSW 2085 Australia

Telephone : + 61 2 9485 1800 Facsimile : + 61 2 9485 1888 Website: www.scigenltd.com